Business Overview: Dalrada Technology Group Inc. (OTC: DHTI)

---

Executive Summary

Dalrada Technology Group Inc. (formerly Dalrada Financial Corporation) is a Wyoming-incorporated, Escondido, California-headquartered micro-cap holding company that operates a collection of small, mostly unrelated operating businesses organized into five divisions: Genefic (specialty pharmacy and healthcare services), Dalrada Climate Technology (heat pumps, energy services, and construction), Dalrada Precision Manufacturing (contract manufacturing and thin-film deposition equipment), Dalrada Technologies (IT/software testing services through its Indian subsidiary Prakat), and Dalrada Corporate (shared administrative functions). The company's pharmacy roots go back more than 30 years, while several of its other units (Dalrada Home, Grand Entrances, the IV Services acquisition) were only added in fiscal 2024-2025.

Dalrada matters less as a scaled industry player and more as a case study in a small, diversified conglomerate attempting a turnaround: it generated roughly $20.3 million in revenue in fiscal year 2025 (ended June 30, 2025) but continues to post large net losses, carries a stockholders' deficit, and has an auditor-issued going-concern qualification. Any read of the business has to be weighed against that financial distress.

Because the five divisions sell into entirely different end markets — specialty pharmacy, HVAC/heat pumps, precision manufacturing/vacuum coating, and IT services — DHTI functions less like a single operating company with one value chain and more like a small holding company; the sections below describe each piece and then roll up the group's consolidated financials.

---

1. Core Business Model & How They Work

Dalrada does not have one unified value chain; each division has its own. At the group level, Dalrada Corporate provides shared finance, legal, HR, IT, and marketing services to the operating divisions, which in turn fund the parent through management fees/consolidated cash flow. A simplified picture of the group structure:

                          DALRADA TECHNOLOGY GROUP INC.
                                      |
        -----------------------------------------------------------------
        |                 |                      |                     |
     GENEFIC        DALRADA CLIMATE        DALRADA PRECISION      DALRADA
   (Healthcare)       TECHNOLOGY            MANUFACTURING       TECHNOLOGIES
        |                 |                      |                     |
  Specialty Rx    ➡️  Heat pumps/HVAC   ➡️   Contract mfg/PVD-CVD  ➡️  Prakat (India)
  Infusion Rx         Energy services        equipment & parts       software testing,
  Lab testing         Construction (Bothof                           digital engineering
  Nursing school       Bros., Dalrada Home,
                        Grand Entrances)

Within a representative division, e.g. Genefic, the flow is a conventional specialty-pharmacy chain: patients/providers ➡️ prescription referral ➡️ Genefic Specialty Pharmacy or Genefic Infusion Rx fills/administers the drug ➡️ reimbursement from insurers/payers. Dalrada Climate Technology instead manufactures/sources heat pumps and chillers, then sells and installs them (via its own contractors) to industrial and residential customers, layering on energy-services and construction revenue. Dalrada Precision Manufacturing is a contract manufacturer plus a maker/refurbisher of physical- and chemical-vapor-deposition (PVD/CVD) equipment sold to other manufacturers. Prakat sells software testing and digital-engineering services on a time-and-materials/project basis to enterprise clients, mostly out of India.

---

2. Business Segments

Fiscal 2025 Revenue Mix ($20.3M total)

Genefic (Healthcare) .................. $10.4M  (~51%)
Dalrada Climate Technology .............  $8.1M  (~40%)
Dalrada Technologies (Prakat) ..........  $1.3M  (~7%)
Dalrada Precision Manufacturing ........  $0.4M  (~2%)
Dalrada Corporate ......................  $0.0M  (0%)

• Genefic (Healthcare) — the largest and most established division, anchored by Genefic Specialty Pharmacy (Alabama-based, licensed in all 50 states and D.C.), Genefic Infusion Rx (Louisiana-based infusion pharmacy), Boost Diagnostics (COVID-19 and genetic lab testing), and the Dalrada Career Institute, a nursing/medical-assistant training school operating since 2006. Segment revenue fell from $13.2M in FY2024 to $10.4M in FY2025, a roughly 21% decline.
• Dalrada Climate Technology — the fastest-growing division, built around proprietary-branded heat pumps (Likido, DCT One, DCT Cryo Chiller), Dalrada Energy Services, general contractor Bothof Brothers Construction, newly formed Dalrada Home, and door/hardware retailer Grand Entrances (acquired in FY2025). Revenue nearly tripled, from $2.8M in FY2024 to $8.1M in FY2025.
• Dalrada Precision Manufacturing — combines Precision Parts contract manufacturing with Deposition Technologies, which builds, sells, and refurbishes PVD/CVD vacuum-deposition systems and OEM replacement parts, plus Ignite, a water-based industrial cleaner/degreaser line. This segment shrank sharply, from $2.4M to $0.4M year over year.
• Dalrada Technologies (Prakat) — an ISO 9001-certified India-based provider of software testing, QA, and digital-engineering services. Revenue was roughly flat at $1.3-1.4M across both years.
• Dalrada Corporate — not a revenue-generating segment; it houses the administrative, finance, legal, HR, IT, marketing, and executive functions that support the other four divisions.

---

3. Key Offerings

---

4. Competitive Landscape

Because DHTI's divisions sit in four unrelated industries, each faces a different, much larger set of competitors, and in every case Dalrada is a sub-scale player:

• Specialty pharmacy/infusion (Genefic): Competes against far larger specialty-pharmacy and infusion operators such as CVS Health (CVS Specialty), Accredo (Cigna/Express Scripts), Option Care Health, and PharMerica — all with vastly greater scale, payer relationships, and distribution networks.
• Heat pumps/HVAC (Dalrada Climate Technology): Competes with established global HVAC manufacturers including Carrier Global, Trane Technologies, Daikin, Mitsubishi Electric, and Rheem, which dominate residential/industrial heat-pump manufacturing and distribution.
• Vacuum deposition equipment (Deposition Technologies): A narrower, more technical niche where competitors include Applied Materials, Veeco Instruments, and specialty equipment makers such as Kurt J. Lesker Company and PVD Products Inc. — Dalrada's unit is tiny by comparison but focuses partly on refurbished/OEM-part niches that larger players underserve.
• IT/software testing (Prakat): Competes against large offshore IT-services firms such as Infosys, TCS, Wipro, HCLTech, and Cognizant, all of which dwarf Prakat in scale and client base.

In short, DHTI holds no segment leadership position in any of its markets; it survives in niches (specialty licensure, refurbished deposition equipment, small-contract IT testing) rather than through scale-based competitive advantage.

---

5. Strategic Strengths & Risks

Strengths / potential moat sources:

• Regulatory licensure — Genefic Specialty Pharmacy's pharmacy licenses across all 50 states and D.C. are a genuine (if narrow) regulatory barrier that a new entrant cannot quickly replicate.
• Longevity in niche training — Dalrada Career Institute has operated continuously since 2006, giving it an accreditation/track-record advantage in its local market.
• Technical specialization in Deposition Technologies — PVD/CVD system refurbishment and OEM parts is a narrow, technically demanding niche with relatively few direct competitors, which can support pricing in that sliver of the business.
• Rapid climate-tech growth — the roughly 188% year-over-year revenue growth in Dalrada Climate Technology (from $2.8M to $8.1M) shows real near-term commercial traction in heat pumps/energy services.

Risks:

• Going-concern doubt — the company's auditor flagged recurring losses and a net capital deficiency that raise substantial doubt about Dalrada's ability to continue as a going concern.
• Stockholders' deficit and working-capital deficit — total stockholders' deficit of $(6,688,417) at June 30, 2025 (versus positive equity of $3,346,107 a year earlier), with current liabilities ($15.7M) far exceeding current assets ($7.7M), a working-capital deficit of roughly $8.0 million.
• Large, persistent net losses — net loss of $24,672,190 in FY2025, following a $29,185,898 loss in FY2024; operating cash burn of $17,972,434 in FY2025.
• Thin, declining cash position — cash and equivalents of only $502,094 at fiscal year-end, a large portion of which ($329,307) is restricted.
• Segment volatility and conglomerate complexity — unrelated businesses (pharmacy, HVAC, vacuum equipment, IT services) make capital allocation and management focus difficult; Precision Manufacturing revenue collapsed roughly 82% year over year while Genefic fell about 21%.
• Litigation and compliance history — multiple pending lawsuits, including a claim involving roughly $2.0 million in unpaid claims, and a disclosure that the company did not file all reports required in the preceding 12 months.
• No R&D investment — reported R&D spending of $0 in both FY2025 and FY2024 limits the company's ability to build genuine technology differentiation going forward.

---

6. Financial Overview

Margins and the working-capital deficit are derived from figures reported in the FY2025 Form 10-K; gross margin percentages are calculated (gross profit ÷ revenue), not figures the filing itself states.

---

7. Summary Conclusion

Dalrada Technology Group is a small, diversified holding company whose value today comes mostly from its legacy Genefic specialty-pharmacy licensure and a fast-growing but still-small Dalrada Climate Technology heat-pump business, with smaller precision-manufacturing and IT-services units rounding out the portfolio. Fiscal 2025 showed genuine operating improvement — gross margin expanded from about 5% to roughly 26%, and the net loss narrowed from the prior year — but these gains have not resolved the company's core financial distress.

With an auditor-issued going-concern qualification, a stockholders' deficit, a working-capital shortfall of roughly $8 million, and only about half a million dollars of cash (much of it restricted), DHTI remains a high-risk, speculative micro-cap. Its individual businesses hold narrow, defensible niches (pharmacy licensure, deposition-equipment refurbishment, a long-running vocational school), but none of them currently generate the scale or cash flow needed to offset the parent company's balance-sheet weakness.